
https://www.science.org/content/blog-post/para-chloro-was-good-enough-them-so-it-s-good-enough-me
# Para-Chloro Was Good Enough For Them, So It's Good Enough For Me (February 2015)

## 1. SUMMARY

This article discusses how historical accidents and path dependence shape medicinal chemistry, focusing on a Journal of Medicinal Chemistry paper from AstraZeneca researchers. The paper demonstrated that drug discovery chemists disproportionately favor para-substituted aromatic compounds (particularly para-chlorophenyl groups) over meta and ortho regioisomers. The authors found this bias reflected in both in-house screening libraries and marketed drugs, suggesting a self-reinforcing cycle: more para-aromatics are commercially available, so more get synthesized, leading to more hits in screening, which further perpetuates the preference. The article argues this represents an unjustified bias that limits exploration of potentially diverse bioisosteres and other substitution patterns, highlighting how drug structures reflect human choices and synthetic accessibility rather than an unbiased sampling of chemical space.

## 2. HISTORY

The 2015 AstraZeneca paper sparked significant discussion and follow-up research on bias in medicinal chemistry. Subsequent studies confirmed and expanded on these findings:

**Academic and Industry Response**: Multiple research groups published analyses showing similar biases in other pharmaceutical companies' compound libraries. The issue gained attention at major conferences (ACS, EFMC, and medicinal chemistry symposia), leading to workshops on designing more diverse screening collections.

**Practical Impact on Drug Discovery**: Several companies (including AstraZeneca, GSK, and Pfizer) publicly discussed efforts to intentionally incorporate more meta- and ortho-substituted building blocks into their screening decks. Academic groups developed systematic approaches to library design that explicitly account for and counteract historical biases.

**Commercial Reagent Availability**: Chemical suppliers responded by expanding their catalogs of meta- and ortho-substituted aromatic building blocks, though para-substituted compounds still dominate many categories due to lower manufacturing costs and established synthetic routes.

**Advancement of Synthetic Methods**: While the article focused on substitution patterns rather than synthesis, the broader conversation it contributed to coincided with increased development of regioselective aromatic substitution methods, including improved metal-catalyzed C-H functionalization techniques that provide better access to meta-substituted arenes.

## 3. PREDICTIONS

- **Prediction (implied)**: That the documented bias would limit discovery of potentially superior drug candidates
  - **Reality**: The bias remains, but increased awareness has led to more intentional library design strategies in major pharmaceutical companies

- **Prediction (implied)**: That synthetic accessibility and commercial availability would continue driving structural choices
  - **Reality**: This remains true, though with expanded commercial availability of previously underrepresented building blocks

- **Prediction (implied)**: That understanding these biases could lead to improved compound library design
  - **Reality**: This has occurred, with systematic approaches to diversity-oriented synthesis and focused library design becoming more sophisticated in pharmaceutical research

## 4. INTEREST

Rating: **7/10**

This article highlights an important but underappreciated constraint in drug discovery - the path-dependent nature of chemical space exploration. It catalyzed discussion about systematic bias in medicinal chemistry and influenced how pharmaceutical companies think about library design.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20150223-para-chloro-was-good-enough-them-so-it-s-good-enough-me.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_